Innovent Biologics, Inc. and Daiichi Sankyo have entered into an exclusive agreement for the commercialisation of Vanflyta® (quizartinib) in China.
Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta® while Innovent Biologics holds sole commercialisation rights for Vanflyta® in China, leading market promotion.
VANFLYTA was approved in China in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an adequate validated diagnostic test, based on the results from the QuANTUM-First trial.
More than 487,000 new cases of leukemia were reported globally in 2022, with more than 305,000 deaths. AML accounts for 23.1% of total leukemia cases worldwide and is most common in adults. In China, nearly 82,000 people were diagnosed with leukemia in 2022 and more than 50,000 people died from the disease, making it the tenth deadliest cancer. AML is a common and aggressive subtype, accounting for approximately 50% of leukemia cases in China.
A number of gene mutations have been identified in AML and FLT3 (FMS-like tyrosine kinase 3) mutations are the most common.Approximately 80% of FLT3 mutations are FLT3-ITD mutations, which drive cancer growth and contribute to particularly unfavorable prognosis, including increased risk of relapse and shorter overall survival. FLT3-ITD mutations occur in about 25% of all AML cases.
Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations.
